Key result
Eltrombopag shows potential in managing HCV-related thrombocytopenia by facilitating antiviral therapy and reducing periprocedural bleeding, despite significant cost and safety concerns.
Why the study?
Does eltrombopag improve thrombocytopenia in patients with hepatitis C virus infection?
Does eltrombopag improve thrombocytopenia in patients with hepatitis C virus infection?
Eltrombopag shows potential in managing HCV-related thrombocytopenia to facilitate antiviral therapy and periprocedural management, but carries significant safety and cost concerns.
Answers are grounded in this paper and cite their sources.
Should not yet change practice for HCV thrombocytopenia; hypothesis-generating for eltrombopag pending randomized trials.
Eltrombopag is a 2nd generation thrombopoietin-receptor agonist. It binds with the thrombopoietin-receptors found on the surfaces of the megakaryocytes & increases platelet production. Many recent studies have suggested a potential role for this novel agent in the treatment of thrombocytopenia associated with hepatitis-C infection. Studies have shown that adjunct treatment with Eltrombopag can help avoid dose reductions/withdrawals of pegylated interferon secondary to thrombocytopenia. It may also have a role in priming up platelet levels to help initiate antiviral therapy. Similarly, chronic liver disease patients with thrombocytopenia who need to undergo an invasive procedure may be potential candidates for short two-week courses of eltrombopag in the periprocedural period to help reduce the risk of bleeding. Besides the price (deemed very expensive and probably not cost-effective), there are some legitimate concerns about the safety profile of this novel agent (most importantly, portal vein thrombosis, bone marrow fibrosis and hepatotoxicity). In this article, the potential role of eltrombopag in the context of hepatitis C virus (HCV)-related thrombocytopenia is reviewed. To write this article, a MEDLINE search was conducted (1990 to November 2012) using the search terms "eltrombopag," "HCV," and "thrombocytopenia."
No takes yet. Share an insight, caveat, or question.
Danish et al. (2013) conducted a review in Hepatitis C virus-related thrombocytopenia. Eltrombopag was evaluated. Eltrombopag shows potential in managing HCV-related thrombocytopenia by facilitating antiviral therapy and reducing periprocedural bleeding, despite significant cost and safety concerns.
Synapse has enriched 10 related papers. Consider them for comparative context: